파머징 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 경제별, 적응증별, 지역별, 부문별 예측(2024-2030년)

Pharmerging Market Size, Share & Trends Analysis Report By Product (Pharmaceutical, Healthcare), By Economy (Tier-1, Tier-2), By Indication (Lifestyle Disease, Infectious Disease), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,302,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,698,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,488,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

파머징 시장의 성장과 동향 :

세계의 파머징 시장 규모는 2030년에 2조 800억 달러에 달할 것으로 예측되며, 2024-2030년 CAGR은 2.6%로 성장할 것으로 예측됩니다.

노인 인구 증가, 만성질환으로 인한 질병 부담 증가, 의료비 지출 증가로 인해 이 시장은 확대될 것으로 예상됩니다.

유엔(UN)에 따르면 2015년 60세 이상 인구는 9억 1,000만 명으로 추산됩니다. 노인 인구 증가는 고지혈증, 고혈압, 암, 치매, 울혈성심부전 등 만성질환에 대한 더 나은 치료 옵션에 대한 수요를 증가시킬 것이며, Deloitte의 2011년 조사에 따르면 노인 인구는 제약 시장의 거의 23.0-40.0%, OTC 제약 시장의 40.0-50.0%를 차지할 것으로 예상됩니다. 시장의 40.0-50.0%를 차지하고 있습니다. 파머징 시장을 촉진하는 또 다른 요인은 의료비 지출 증가입니다.

세계 보건 관측소(Global Health Observatory)의 데이터에 따르면 2015년 사망원인의 70.0%가 비감염성 질환(NCD)으로 인한 것으로 나타났습니다. 주요 NCD는 심혈관 질환(CVD)이 45.0%, 암이 22.0%, 만성폐쇄성폐질환(COPD)이 10.0%, 당뇨병이 4.0%를 차지하며 NCD 사망자의 45.0%를 차지했습니다.

파머징 시장 하이라이트

• 제약 분야는 2023년 85.0%의 가장 큰 매출 점유율을 차지하며 시장을 장악했습니다.
• Tier-1 경제권이 시장을 주도하며 2023년 시장 점유율이 60.5%로 가장 높을 것으로 예상됩니다.
• 주요 전략적 노력으로는 신제품 출시, 인수합병, 제휴 등이 있습니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 파머징 시장의 변수, 동향, 범위

• 시장 서론/계통 전망
• 시장 규모와 성장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 파머징 시장 분석 툴
  • Porter의 산업 분석
  • PESTEL 분석

제4장 파머징 시장 : 제품 추정·동향 분석

• 부문 대시보드
• 파머징 시장 : 제품별 변동 분석, 2023년·2030년
• 제약
• 기타 헬스케어 업계

제5장 파머징 시장 : 경제 추정·동향 분석

• 부문 대시보드
• 파머징 시장 : 경제별 변동 분석, 2023년·2030년
• Tier 1
• Tier 2
• Tier 3

제6장 파머징 시장 : 적응증 추정·동향 분석

• 부문 대시보드
• 파머징 시장 : 적응증별 변동 분석, 2023년·2030년
• 생활습관병
• 암과 자가면역질환
• 감염증
• 기타

제7장 파머징 시장 : 지역 추정·동향 분석

• 파머징 시장 점유율, 지역별, 2023년·2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
• 기업 분류
• 기업 히트맵 분석
• 기업 개요
  • Sanofi
  • Pfizer Inc.
  • AstraZeneca
  • GlaxoSmithKline
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare
  • Eli Lilly and Company
  • Medtronic
  • Abbott
  • Johnson and Johnson

KSA

영문 목차

영문목차

Pharmerging Market Growth & Trends:

The global pharmerging market size is expected to reach USD 2.08 trillion in 2030 and is projected to grow at a CAGR of 2.6% from 2024 to 2030. This market is expected to grow due to the increasing geriatric population, increasing disease burden of chronic disorders, and increasing healthcare expenditure.

According to the United Nations (UN), the number of people above the age of 60 years is estimated to be 901 million in 2015. The increasing geriatric population boosts the demand for better treatment options for chronic diseases such as hyperlipidemia, hypertension, cancer, dementia, congestive heart failure. According to a study conducted by Deloitte in 2011, the geriatric population accounts for almost 23.0-40.0% of the prescription drug market, and 40.0-50.0% of the OTC drug market. Another driving factor for the pharmerging market is increasing healthcare expenditure.

The increasing disease burden of chronic diseases in developing countries is boosting growth in the market. According to the Global Health Observatory data, in 2015, 70.0% of the deaths were due to non-communicable diseases (NCD). The major NCDs are cardiovascular diseases (CVD) which caused 45.0% of all NCD deaths, cancer which caused 22.0% of all NCD deaths and chronic obstructive pulmonary disease (COPD) which causes 10.0% of all NCD deaths, and diabetes which caused 4.0% of all NCD deaths.

Pharmerging Market Report Highlights:

• The pharmaceutical product segment dominated the market and accounted for the largest revenue share of 85.0% in 2023.
• The tier-1 economy led the market, accounting for the largest market share at 60.5% in 2023.
• The key strategic initiatives include new product launches, acquisitions and mergers, and collaborations.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Pharmerging Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Billion)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Pharmerging Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Pharmerging Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Pharmerging Market: Product Movement Analysis, 2023 & 2030 (USD Billion)
• 4.3. Pharmaceutical
  • 4.3.1. Pharmaceutical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.1.1. Patented Prescription Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.1.2. Generic Prescription Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.1.3. OTC Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 4.4. Other Healthcare Verticals
  • 4.4.1. Other Healthcare Verticals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.1.1. Medical Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.1.2. Clinical Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.1.3. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Pharmerging Market: Economy Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Pharmerging Market: Economy Movement Analysis, 2023 & 2030 (USD Billion)
• 5.3. Tier-1
  • 5.3.1. Tier-1 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.4. Tier-2
  • 5.4.1. Tier-2 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.5. Tier-3
  • 5.5.1. Tier-3 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Pharmerging Market: Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Pharmerging Market: Indication Movement Analysis, 2023 & 2030 (USD Billion)
• 6.3. Lifestyle Diseases
  • 6.3.1. Lifestyle Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.4. Cancer & Autoimmune Diseases
  • 6.4.1. Cancer & Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.5. Infectious Diseases
  • 6.5.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 6.6. Others
  • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Pharmerging Market: Regional Estimates & Trend Analysis

• 7.1. Pharmerging Market Share, By Region, 2023 & 2030 (USD Billion)
• 7.2. North America
  • 7.2.1. North America Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.2.3. Canada
    • 7.2.3.1. Canada Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.3. Europe
  • 7.3.1. Europe Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3.2. UK
    • 7.3.2.1. UK Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3.3. Germany
    • 7.3.3.1. Germany Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3.4. France
    • 7.3.4.1. France Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3.5. Italy
    • 7.3.5.1. Italy Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3.6. Spain
    • 7.3.6.1. Spain Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3.9. Norway
    • 7.3.9.1. Norway Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.3. China
    • 7.4.3.1. China Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.4. India
    • 7.4.4.1. India Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.5. Australia
    • 7.4.5.1. Australia Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.6. South Korea
    • 7.4.6.1. South Korea Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.7. Thailand
    • 7.4.7.1. Thailand Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.5. Latin America
  • 7.5.1. Latin America Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.4. UAE
    • 7.6.4.1. UAE Pharmerging Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Pharmerging Market Estimates and Forecasts, 2018 - 2030) (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. Sanofi
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Recent Developments/ Strategic Initiatives
  • 8.4.2. Pfizer Inc.
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Recent Developments/ Strategic Initiatives
  • 8.4.3. AstraZeneca
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Recent Developments/ Strategic Initiatives
  • 8.4.4. GlaxoSmithKline
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Recent Developments/ Strategic Initiatives
  • 8.4.5. F. Hoffmann-La Roche Ltd.
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Recent Developments/ Strategic Initiatives
  • 8.4.6. GE Healthcare
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Recent Developments/ Strategic Initiatives
  • 8.4.7. Eli Lilly and Company
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Recent Developments/ Strategic Initiatives
  • 8.4.8. Medtronic
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Recent Developments/ Strategic Initiatives
  • 8.4.9. Abbott
    • 8.4.9.1. Participant's Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Recent Developments/ Strategic Initiatives
  • 8.4.10. Johnson and Johnson
    • 8.4.10.1. Participant's Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Recent Developments/ Strategic Initiatives

관련자료